Vir Biotechnology Q2 net income $80.1M on Astellas deal; cash $1.01B

Vir Biotechnology, Inc.

Net income of $80.1M ($0.48 diluted EPS) vs net loss of $111.0M in Q2 2025.
Revenue $238.9M, primarily from $240M Astellas upfront payment; cash $1.01B.
Phase 2 SOLSTICE: 88% of CHD patients achieved undetectable HDV RNA at Week 96.
Phase 3 ECLIPSE 1 topline data expected Q4 2026; ECLIPSE 2 fully enrolled.
Appointed Timothy Coughlin to Board and as Audit Committee Chair.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.